American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

Рекомендации Американской коллегии ревматологов 2008 года по применению небиологических и биологических базисных противоревматических препаратов при ревматоидном артрите
Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar, Jeremy Anuntiyo, Catherine Finney, Jeffrey R. Curtis, Harold E. Paulus, Amy S. Mudano, Maria Pisu, Mary Elkins-Melton, Ryan C. Outman, Jeroan J. Allison, Maria Suarez Almazor, S. Louis Bridges, W. Winn Chatham, Marc C. Hochberg, Catherine H. MacLean, Ted R. Mikuls, Larry W. Moreland, James R. O’Dell, Anthony Turkiewicz, Daniel E. Furst
2008-05-30

American College of Rheumatologybiologic DMARDsdisease-modifying antirheumatic drugsnonbiologic DMARDsrheumatoid arthritis
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
1
Application of the recommendations is voluntary and should be determined by physicians according to each patient’s circumstances.
2
The American College of Rheumatology developed recommendations for using nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
3
The recommendations aim to promote beneficial outcomes but cannot guarantee specific results.
4
The recommendations are subject to periodic revision as medical knowledge, technology, and clinical practice evolve.
5
The recommendations provide guidance for particular clinical practice patterns rather than dictating treatment for individual patients.

Use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

ACR 2008 recommendations and practice guidance for drug use, tailored to individual patient circumstances

Publication Details
Publication Date
2008-05-30
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Kenneth G. Saag
Gim Gee Teng
Nivedita M. Patkar
Jeremy Anuntiyo
Catherine Finney
Jeffrey R. Curtis
Harold E. Paulus
Amy S. Mudano
Maria Pisu
Mary Elkins-Melton
Ryan C. Outman
Jeroan J. Allison
Maria Suarez Almazor
S. Louis Bridges
W. Winn Chatham
Marc C. Hochberg
Catherine H. MacLean
Ted R. Mikuls
Larry W. Moreland
James R. O’Dell
Anthony Turkiewicz
Daniel E. Furst
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%